On this page, you may find all recent information on the ADDIA project, and its progress.
For further information on Amoneta and ADDIA Test, please contact us here.
Alzheimer Europe published an article on Amoneta's ADDIA Biobank
Alzheimer Europe, the leading European organization which brings together and represents 42 member associations from 37 countries, published an article on the ADDIA Biobank of Amoneta; on its "Science Watch" section, as a breakthrough headline in the field of Dementia.
You may read the full article here: https://www.alzheimer-europe.org/News/Science-watch/Tuesday-20-November-2018-Amoneta-Diagnostics-describes-its-biobank-of-biological-samples-from-patients-with-dementia-and-cognitively-intact-subjects
ADDIA is presented at the Alzheimer's Association International Conference (AAIC)
The progress of ADDIA clinical studies and the results obtained on blood-based biomarker tests were presented at the AAIC 2018, in Chicago.
For more information please refer to the following link:
ADDIA Clinical Investigators met in Strasbourg and planned the end of study
ADDIA Project Clinical Investigator Team met for the 3rd time, in Strasbourg. Team discussed the excellent results obtained on blood biomarkers on samples from the Chronobiological study and went through the overall plan to complete the clinical study.
ADDIA Team 2nd Annual Meeting took place in Strasbourg
The 2nd of ADDIA Clinical Investigators Meeting took place, on the 3rd of July 2017, in Strasbourg. The team discussed the significant achievements in the progress of the clinical studies and decided next steps of the ADDIA study.
SCIENTIFIC AMERICAN Article points to the need for
New Biomarkers to diagnose Alzheimer's Disease in blood
The Scientific American published an article written by Dr. Howard Fillit, the Founding Executive Director and Chief Science Officer at the Alzheimer's Drug Discovery Foundation (ADDF), one of the most acknowledged Key Opinion Leaders in the field of Alzheimer's Disease.
The article points to the unmet need for blood biomarkers for an inexpensive and noninvasive clinical diagnosis of Alzheimer's Disease. According to Dr. Fillit, such a test would not only facilitate the diagnosis but also stimulate better treatments for the Alzheimer's Disease, for which (in sharp contrast to other illnesses and
despite many efforts as well as huge expenses and hundreds of clinical trials), no new treatment have been approved in the past 16 years.
Click here to view the original article from Scientific American webpage.
This article confirms, the real value of ADDIA, a blood diagnostic test based on a combination of 2 biomarkers. ADDIA is a multicentric proof-of-performance biomarker study, funded by the European Union Horizon-2020 Program.
Authorizations for Human Samples Transportation: Amoneta Diagnostics obtained the authorization by the French Ministry of Education and Research “Ministère de l’éducation Nationale, de l’enseignement Supérieuret de la Recherche” for human sample importation from the ADDIA Clinical centers in Italy, Switzerland, Turkey, Belgium and Canada.
Chronobiological Study Recruits: First subjects are recruited for the ADDIA chronobiological study, upon informed consents signed during 4Q 2016.
ADDIA recruited first subjects!
ADDIA PoP clinical study on 800 subjects(*) is initiated with the first subjects included on Jan 16, 2017 in Brescia and Strasbourg clinical sites; also on Feb 10 2017 in Istanbul clinical site.
*400 patients with Alzheimer’s disease, 200 with non-Alzheimer neurodegenerative diseases and 200 healthy controls.
Centre Hospitalier Universitaire Vaudois (CHUV)
Lausanne/Switzerland (Prof. JF. Démonet on the right)
Chronobiological Study Initiated: The clinical chronobiological study on 12 patients with Alzheimer’s disease and 12 healthy controls is initiated, with the first informed consents signed during 4Q 2016.
ADDIA Data-Monitoring Assured: Amoneta Diagnostics S.A.S., coordinator of the ADDIA Project, signed a contract with DrPospichal-Mediante GmbH for the data monitoring of the ADDIA Proof-Of-Performance (PoP) clinical study. DrPospichal-Mediante GmbH is an independent contract research organizations (CROs) based in Germany, with experience in providing clinical research services to the biopharmaceutical industry and life science organizations.
Amoneta signs for ADDIA e-CRF Service: Amoneta Diagnostics S.A.S., coordinator of the ADDIA Project, signed a contract with Absilon to perform the Electronic Clinical Research Form (e-CRF) of the ADDIA Proof-Of-Performance (PoP) clinical study. Absilon is an independent CRO based in France, with experience in providing clinical research services to the biopharmaceutical industry.
ADDIA obtains Ethic Committee Approvals: Amoneta Diagnostics SAS successfully submitted the ADDIA PoP clinical study package to and obtained approval from the ethic committees of France on 4-Jul-2016, Italy on 19-Oct-2016, Turkey on 28-Jun-2016, Switzerland on 5-Sep-2016 as well as from the French “Agence Nationale de Sécurité du Médicament et des Produits de Santé” on 1-July-2016.
ADDIA Chronobiological Study obtains Approvals: Amoneta Diagnostics S.A.S. obtained the approval from the French ethic committees “Comité de Protection des Personnes” (CPP) also on June 14, 2016 from the ”Agence Nationale de Sécurité du Médicament et des Produits de Santé” (ANSM) for its chronobiological study that will include patients with Alzheimer’s disease and healthy controls.
ADDIA Project launched with a Consortium Kick-off Meeting
In coordination of Amoneta Diagnostics S.A.S. and with participation of several clinical centers, ADDIA project is launched via an excellent kick-off meeting, in the administrative site of Amoneta in Huningue, at the triple border of France, Switzerland (Basel Region) and Germany (Freiburg). All parties have represented their institutes, specialities and capabilities by focused and uniformed presentations.
Firalis S.A., the parent company of Amoneta Diagnostics S.A.S. and a partner of ADDIA project (as third linked party), as well as other stakeholders such as consultants and outsourcing partners, were also present at the meeting.
Next step is to have further discussions with each of the stakeholders and clinical centers in particular, in order to prepare the clinical trial in a best possbile configuration.